摘要：
目的：基于基因组高通量测序筛选前列腺癌患者血液中异常表达的miRNAs，并验证其结果。材料与方法：选取在宜春市人民医院泌尿外科的前列腺癌患者、前列腺增生患者及健康人群的血液标本，采用RNA测序（RNA sequencing，RNA-seq）进行测序分析，并运用荧光定量聚合酶链反应（RT-PCR）验证外周血标本中超过10倍以上差异表达基因。通过RT-PCR验证人前列腺癌细胞中miR-429被敲低后的表达水平；分别运用细胞计数试剂盒（CCK-8）实验和EdU细胞染色实验检测细胞的增殖功能。结果：根据测序结果，挑选出在前列腺癌患者外周血中明显高表达的4种miRNAs：miRNA-429、miR-23a、miR-193a和miR-216a-5p，构建相对应的引物，并通过RT-PCR在前列腺癌在患者进行验证发现仅miRNAs-429表达差异较为明显。构建的miRNAs-429质粒可显著上调的前列腺癌细胞增殖能力，并降低细胞凋亡。结论：miRNAs-429的异常表达对前列腺癌细胞增殖和细胞凋亡均有影响，这些结果表明miRNAs-429在前列腺癌的发生、发展中可能发挥重要的作用。

关键词：前列腺癌；miRNA；miR-429；细胞增殖；测序

Abstract:
Objective: To screen the abnormal expression of miRNAs in the blood of prostate cancer patients based on high-throughput genome sequencing and verify the results. Materials and Methods: Blood samples from prostate cancer patients, prostate hyperplasia patients and healthy people in the Department of Urology of Yichun People's Hospital were selected for analysis through RNA sequencing (RNA-SEQ). Fluorescence quantitative polymerase chain reaction (RT-PCR) was used to verify more than 10 times differentially expressed genes in peripheral blood samples. The expression level of miR-429 in human prostate cancer cells after knockdown was verified by RT-PCR. Cell counting kit (CCK-8) assay and EdU cell staining assay were used to detect cell proliferation. Results: According to the sequencing results, 4 miRNAs with high expression in peripheral blood of patients with prostate cancer were selected: The corresponding primers were constructed for miRNA-429, miR-23a, miR-193a and miR-216a-5p, and it was found that only miRNAs-429 expression was significantly different in patients with prostate cancer by RT-PCR. The constructed miRNAs-429 plasmid can significantly up-regulate the proliferation of prostate cancer cells and reduce cell apoptosis. Conclusion: The abnormal expression of miRNAs-429 may affect the proliferation and apoptosis of prostate cancer cells. These results suggest that miRNAs-429 may play an important role in the occurrence and development of prostate cancer.

Keywords: Prostate cancer; miRNA; miR-429; Cell proliferation; Sequencing

正文内容 / Content：

可下载并阅读全文PDF，请按照本文版权许可使用。

Download the full text PDF for viewing and using it according to the license of this paper.

参考文献 / References：

Liu X, Yu C, Bi Y, et al.Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China[J]. Public Health, 2019, 172:70-80. DOI:10.1016/j.puhe.2019.04.016.
Zhou J, Yang X, Song P, Wang H, Wang X. HOXC6 in the prognosis of prostate cancer.Artificial Cells, Nanomedicine, and Biotechnologyl. 2019;47(1):2715-2720.
Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. Journal of Medicine and Life. 2017;10(1):5-12.
Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. The World Journal of Men's Health. 2019;37(3):288-295.
Arai T, Okato A, Yamada Y, et al. Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC. Cancer Medicine. 2018;7(5):1988-2002.
Groot M, Lee H. Sorting Mechanisms for MicroRNAs into Extracellular Vesicles and Their Associated Diseases. Cells, 2020, 9(4): pii: E1044.
Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. The EMBO Journal, 2004, 23(20):4051-4060.
Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Current Biology , 2004, 14(23):2162-2167.
Clancy JW, Zhang Y, Sheehan C, et al. An ARF6-Exportin-5 axis delivers pre-miRNA cargo to tumour microvesicles. Nature Cell Biology, 2019, 21(7):856-866.
Michlewski G, Cáceres JF. Post-transcriptional control of miRNA biogenesis. RNA, 2019, 25(1):1-16.
McGeary SE, Lin KS, Shi CY，et al. The biochemical basis of microRNA targeting efficacy. Science, 366(6472), eaav1741..
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2):215-33.
Dai M, Li L, Qin X. Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer. Oncology letters, 2019, 17(4):3919-3929.
Nam HS, Hwang KS, Jeong YM, et al. Expression of miRNA-122 Induced by Liver Toxicants in Zebrafish. Biomed Res Int, 2016, 2016:1473578.
Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Molecular Cell, 2008, 30(4):460-471.
Wang S, Pan Y, Zhang R, et al. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5. Oncogene, 2016, 35(47):6096-6108.
Olejniczak M, Kotowska-Zimmer A, Krzyzosiak W. Stress-induced changes in miRNA biogenesis and functioning. Cellular and Molecular Life Sciences, 2018, 75(2):177-191.
Ye Y, Li SL, Wang SY. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer. PLoS One, 2018, 13(8):e0198055.
Yu Q, Zhang Z, He B, et al. MiR-543 functions as tumor suppressor in ovarian cancer by targeting TWIST1. Journal of Biological Regulators and Homeostatic Agents, 2020, 34(1):101-110.
Beard JA, Tenga A, Hills J, et al. The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network. Scientific Reports, 2016, 6:25108.
Malpeli G, Barbi S, Tosadori G, et al. MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget, 2018, 9(51):29753-29771.
Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer letters. 2017;407:9-20.